Experts at AMCP Nexus say biosimilar launches should prompt payers to revisit step therapy and measure value beyond market share.
|Articles|October 5, 2012
VIDEO: Aimee Tharaldson, PharmD, Discusses the Impact of Biosimilars on the Specialty Pharmacy Market
In this video, Aimee Tharaldson, PharmD, Senior Clinical Consultant, Emerging Therapeutics Express Scripts, Inc, talks about the impact that biosimilar medications could potentially have on the specialty pharmacy market.
Advertisement
In this video, Aimee Tharaldson, PharmD, Senior Clinical Consultant, Emerging Therapeutics Express Scripts, Inc, talks about the impact that biosimilar medications could potentially have on the specialty pharmacy market.
Although Dr. Tharaldson says that there has not been an impact yet, she says that "eventually, once more guidance is available, we will see more of the true biosimilars approved. Once we can get these to be interchangable at the point of service -- that's where we're going to see a lot of cost savings."
This video was taken on Thursday, October 4, 2012, at the Academy of Managed Care Pharmacy's 2012 Educational Conference in Cincinnati, OH.
Advertisement
Related to this article
Early modeling put sickle cell gene therapy coverage near 11 cents per member per month.
At AMCP Nexus 2026, payers said evidence, differentiation, and delivery now matter as much as FDA approval.
Three experts apply policy, pharmacy operations, and member-level lenses to the same prescriptions to show why cost at the counter decides adherence.
Norah Terrault, MD, MPH, on why few diagnosed patients reach HCV cure and how primary care test-and-treat can close the gap.
HHS enforcement discretion lets state pharmacies compound BPC-157 and other peptides amid rulemaking and legal challenges.
HHS does not intend to take enforcement action against pharmacies compounding BPC-157 and 5 other unapproved peptides if they meet 10 conditions.
At an AJMC® Stakeholder Interchange in Los Angeles, leukemia specialists described a region where hospital formularies push menin inhibitor starts into the clinic, emergency department (ED) physicians may not recognize differentiation syndrome, and capitated insurance contracts steer some patients with acute myeloid leukemia away from academic centers.
Advertisement
Advertisement
Trending on AJMC
1
HHS Draft Policy Eases Enforcement on 6 Compounded Peptides
2
BPC-157 'Wolverine Peptide' Use Rose 33-Fold Despite Scant Evidence
3
5 Things to Know About HHS's Interim Peptide Compounding Policy
4
340B Reform, PBM Policy Among 2027 Issues to Watch: Adam Colborn, JD
5